Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings, Inc.

We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Oxford Finance LLC

Silicon Valley Bank

Armistice Capital

Deerfield

Asahi Kasei

Palmetto Partners

Bay City Capital

Wild Basin Investments

Merieux Developpement

Xeris Pharmaceuticals, Inc.

Wishing health, happiness, and prosperity to all celebrating the Lunar New Year! 
 
As many welcome the Year of the Dragon this week with hopes for a lucky year ahead, we at Xeris join in honoring the occasion. May it bring new beginnings filled with joy.
 
The values of compassion, care and community at the heart of this holiday inspire us daily in our mission. However you mark this festive time of renewal, we wish you the very best in the year to come.

#LunarNewYear #LunarNewYear2024 #YearOfTheDragon

Meet Emily, one of our Cushing’s Syndrome Patient Voices. In 2015, Emily’s diagnosis of Cushing’s came a year and a half after scans showed benign tumors on both of her adrenal glands. Her original endocrinologist did not look for Cushing’s, and it was not until she saw a new endocrinologist that her Cushing’s was diagnosed.

Although Emily does not look like other individuals who live with Cushing’s— for example, she is not overweight — an endocrinologist she saw for a routine follow-up check on her adrenal tumors noticed her cortisol was elevated and sent her to a Cushing’s specialist. That endocrinologist diagnosed Cushing’s.
 
Unfortunately, delay in diagnosis is far too common for many individuals living with a rare disease. Emily's advice to others living with Cushing's is to "remember that Cushing’s can look different in different people and remain compassionate — for yourself and others.”

We take pride in supporting #RareDiseaseMonth this February to raise awareness for those living with Cushing's and supporting those who treat it. We understand Cushing's is not a "one size fits all approach."

Connect with us through Xeris CareConnection™ to speak with a Patient Access Manager and learn more about Emily's story. Click here to sign up for support: https://lnkd.in/gPXvi5ZC
 
#Cushings #CushingDisease #CushingsSyndrome #RareDisease

We are so excited to be exhibiting at #PriMedSouth in Fort Lauderdale later this week! Visit Booth #322 to learn about the importance of having a safety net if you or a loved one is at risk for very low blood sugar. If you’re attending, let us know in the comments! 

Pri-Med

We are so honored to have our Gvoke HypoPen® influencer campaign chosen out of over 2,000 entries as both a Bronze Anthem Winner and a Community Voice Award Winner in the Social Media Content, Campaign or Channel category. Thank you to The Anthem Awards for recognizing the importance of equipping diabetes patients with a safety net to treat very low blood sugar. 
 
Check out our call to action here: https://lnkd.in/gPT9r2Qc and learn more about Gvoke HypoPen® (glucagon injection) at https://lnkd.in/gJX_xGiu.

#AnthemAwards #Diabetes #DiabetesAwareness #DiabetesCommunity #InfluencerMarketing #GvokeHypoPen

What is GVOKE? GVOKE is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 2 years and above. It is not known if GVOKE is safe and effective in children under 2 years of age.

Do not use GVOKE if: you have a tumor in the gland on top of your kidneys (adrenal gland) called a pheochromocytoma, as it may cause a substantial increase in blood pressure; you have a tumor in your pancreas called an insulinoma, as it may cause low blood sugar; or if you are allergic to glucagon or any inactive ingredient in GVOKE.

GVOKE may cause other serious side effects, such as Serious skin rash -- in certain people with a tumor in their pancreas called a glucagonoma; Serious allergic reactions -- Call your doctor or get medical help right away if you have a serious allergic reaction including rash, difficulty breathing, low blood pressure.

See Important Safety Information: https://lnkd.in/gA79wrqT
 
See Full Prescribing Information: https://bit.ly/3baHqAO

Meet Jodi, one of our Cushing’s Syndrome Patient Voices. For Jodi, receiving a Cushing's diagnosis was validating because she had always believed her Cushing's-related symptoms were not her fault. A diagnosis proved to her that she was not to be blamed for her symptoms. 
 
As we shine a light on our patient voices throughout #RareDiseaseMonth, we encourage those living with a rare disease to always advocate for themselves just like Jodi has. We take pride in supporting Rare Disease Month this February to raise awareness for those living with Cushing’s and supporting those who treat it. Connect with us through Xeris CareConnection™ to speak with a Patient Access Manager and learn more about Jodi's story. Click here to sign up for support: https://lnkd.in/gPXvi5ZC
 
#Cushings #CushingDisease #CushingsSyndrome #RareDisease

Join clinical experts  David Lieb, MD, FACE, Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, and Vin Tangpricha, MD, PhD, FACE as they discuss the 2022 AACE diabetes guideline updates and address the issue, “How Should Hypoglycemia Be Managed? Listen to the podcast today!

Are you looking for a rewarding new opportunity?

We're #hiring two Area Business Specialists to join the Xeris team!

To learn more and apply, visit https://bit.ly/499XFcU

#PharmaJobs #RareDiseases

Today, we join millions nationwide in remembrance of civil rights leader Dr. Martin Luther King Jr. His leadership and advocacy during the Civil Rights Movement led to monumental societal shifts that continue to pave the way for equality.
 
Dr. King organized peaceful demonstrations and delivered legendary speeches like "I Have a Dream" to galvanize support to end segregation and secure voting rights for all. His nonviolent resistance and call for people of all races, religions and backgrounds to unite in fellowship deeply impacted the conscience of America. 
 
Even with major milestones accomplished, Dr. King's dream remains unfinished. As we pause to honor his courage, we also recommit ourselves to enacting change. At Xeris, this means fostering a diverse, equitable and inclusive culture where all our employees feel welcomed, valued and empowered. We strive to incorporate Dr. King's values of compassion and human dignity into every aspect of our work.
 
We hope Dr. King's extraordinary message resonates with all our connections near and far.

#MLKDay #MartinLutherKingJr

If you're interested in working in the #diabetes space, we're hiring for Territory Business Representatives, Diabetes in Atlanta West, Omaha, Tulsa, and Central Georgia. Apply now! https://lnkd.in/gt82PnVe

#DiabetesCommunity #Hiring

Exciting news! Today we announced that Xeris has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab (known as TEPEZZA® in the United States) using our XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease. 

Read more: https://lnkd.in/gPcdGCVZ 

#ThyroidEyeDisease #PharmaNews #Pharmaceuticals

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	1.07M -	1.56M 44.74%	2.46M 58.42%	20.16M 717.65%	49.59M 146.04%	110.25M 122.32%	110.25M 0%	163.91M 48.68%
cost of revenue	8K -	4K 50%	42K 950%	9.33M 22,109.52%	13.32M 42.77%	22.63M 69.95%	22.63M 0%	39.49M 74.46%
gross profit	1.07M -	1.55M 45.45%	2.42M 56.12%	10.83M 346.84%	36.27M 235.01%	87.61M 141.55%	87.61M 0%	124.43M 42.02%
selling and marketing expenses
general and administrative expenses	4.06M -	8.02M 97.41%	21.11M 163.42%
selling general and administrative expenses	4.06M -	8.02M 97.41%	21.11M 163.42%	73.73M 249.23%	125.72M 70.51%	137.75M 9.57%	137.75M 0%	146.09M 6.06%
research and development expenses	10.24M -	20.17M 96.97%	40.65M 101.60%	20.92M 48.54%	25.16M 20.26%	20.97M 16.67%	20.97M 0%	22.34M 6.56%
other expenses	-5K -	-1K 80%		-280K -	550K 296.43%	10.84M 1,871.45%	-14.14M 230.44%
cost and expenses	14.31M -	28.18M 97.02%	61.81M 119.30%	103.70M 67.78%	164.75M 58.87%	192.19M 16.66%	192.19M 0%	207.92M 8.19%
operating expenses	14.30M -	28.18M 97.10%	61.77M 119.18%	94.37M 52.79%	151.43M 60.46%	169.55M 11.97%	169.55M 0%	168.44M 0.66%
interest expense	2K -	2K 0%	2.54M 127,150%	10.66M 318.86%	7.18M 32.65%	15.32M 113.44%	15.32M 0%	26.61M 73.63%
ebitda	-13.12M -	-26.33M 100.75%	-57.73M 119.27%	-80.58M 39.58%	-114.61M 42.22%	-71.10M 37.96%	-71.10M 0%	-30.85M 56.61%
operating income	-13.23M -	-26.63M 101.26%	-59.34M 122.85%	-83.55M 40.78%	-115.16M 37.84%	-81.94M 28.84%	-81.94M 0%	-44.01M 46.29%
depreciation and amortization	116K -	177K 52.59%	320K 80.79%	2.96M 826.56%	550K 81.45%	10.84M 1,871.45%	10.84M 0%	13.16M 21.37%
total other income expenses net	19K -	-47K 347.37%	196K 517.02%	-7.70M 4,030.61%	-7.57M 1.75%	-14.14M 86.87%	-14.14M 0%	-19.49M 37.83%
income before tax	-13.21M -	-26.55M 101.03%	-60.08M 126.26%	-91.25M 51.88%	-122.72M 34.49%	-96.08M 21.71%	-96.08M 0%	-63.50M 33.91%
income tax expense	-3K -	1K 133.33%	1.81M 180,800%	-110K 106.08%	-110K 0%	-1.42M 1,194.55%	-1.42M 0%	-1.25M 12.29%
net income	-13.21M -	-26.55M 101.03%	-60.08M 126.26%	-91.14M 51.70%	-122.72M 34.66%	-94.66M 22.87%	-94.66M 0%	-62.26M 34.23%
weighted average shs out	1.84M -	2.03M 10.08%	12.05M 493.92%	26.11M 116.75%	42.64M 63.32%	79.03M 85.32%	135.63M 71.62%	137.67M 1.51%
weighted average shs out dil	1.84M -	2.03M 10.09%	12.05M 493.92%	26.11M 116.75%	42.64M 63.32%	79.03M 85.32%	135.63M 71.62%	137.67M 1.51%
eps	-7.17 -	-13.09 82.57%	-4.99 61.88%	-3.49 30.06%	-2.88 17.48%	-1.20 58.33%	-0.70 41.67%	-0.45 35.71%
epsdiluted	-7.17 -	-13.09 82.57%	-4.99 61.88%	-3.49 30.06%	-2.88 17.48%	-1.20 58.33%	-0.70 41.67%	-0.45 35.71%

NASDAQ:XERS

Xeris Biopharma Holdings, Inc.

Last Close

2.02

17/05 20:00

Market Cap

343.93M

Beta: -

Volume Today

1.24M

Avg: 1.25M

PE Ratio

−4.97

PFCF: −4.75